Crispr Therapeutics (NASDAQ:CRSP) was downgraded by ValuEngine from a “hold” rating to a “sell” rating in a note issued to investors on Friday, January 3rd, ValuEngine reports.

A number of other analysts have also issued reports on the company. Chardan Capital reaffirmed a “buy” rating and issued a $72.50 target price on shares of Crispr Therapeutics in a report on Monday, November 18th. Canaccord Genuity raised their target price on Crispr Therapeutics from $72.00 to $80.00 and gave the company a “positive” rating in a report on Wednesday, November 20th. Goldman Sachs Group raised their target price on Crispr Therapeutics from $52.00 to $75.00 and gave the company a “neutral” rating in a report on Tuesday, November 19th. William Blair raised Crispr Therapeutics from a “market perform” rating to an “outperform” rating in a report on Tuesday, November 19th. Finally, BidaskClub lowered Crispr Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, January 1st. Three investment analysts have rated the stock with a sell rating, one has given a hold rating and twelve have assigned a buy rating to the company. Crispr Therapeutics currently has an average rating of “Buy” and an average target price of $75.95.

Shares of NASDAQ CRSP traded down $1.82 during mid-day trading on Friday, reaching $54.75. 1,224,856 shares of the company traded hands, compared to its average volume of 1,021,665. The company has a debt-to-equity ratio of 0.06, a quick ratio of 8.32 and a current ratio of 8.32. The stock has a market cap of $3.12 billion, a PE ratio of -119.02 and a beta of 3.20. The company’s fifty day moving average is $63.18 and its two-hundred day moving average is $52.50. Crispr Therapeutics has a fifty-two week low of $29.34 and a fifty-two week high of $74.00.

Crispr Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings data on Monday, October 28th. The company reported $2.40 EPS for the quarter, beating the Zacks’ consensus estimate of ($0.95) by $3.35. The business had revenue of $211.93 million for the quarter, compared to analyst estimates of $6.32 million. Crispr Therapeutics had a negative return on equity of 2.60% and a negative net margin of 5.30%. Research analysts forecast that Crispr Therapeutics will post 0.65 earnings per share for the current year.

In other Crispr Therapeutics news, President Rodger Novak sold 33,618 shares of Crispr Therapeutics stock in a transaction on Tuesday, November 19th. The stock was sold at an average price of $70.00, for a total value of $2,353,260.00. Following the completion of the transaction, the president now owns 33,618 shares in the company, valued at approximately $2,353,260. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Pablo J. Cagnoni sold 7,500 shares of Crispr Therapeutics stock in a transaction on Wednesday, October 30th. The shares were sold at an average price of $52.00, for a total value of $390,000.00. Following the completion of the transaction, the director now owns 7,500 shares of the company’s stock, valued at approximately $390,000. The disclosure for this sale can be found here. Insiders have sold a total of 56,118 shares of company stock valued at $3,620,760 in the last 90 days. 21.40% of the stock is owned by corporate insiders.

Several hedge funds have recently added to or reduced their stakes in CRSP. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of Crispr Therapeutics by 13.6% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,870 shares of the company’s stock worth $118,000 after purchasing an additional 343 shares during the period. Traynor Capital Management Inc. grew its stake in Crispr Therapeutics by 5.8% in the third quarter. Traynor Capital Management Inc. now owns 6,845 shares of the company’s stock valued at $280,000 after acquiring an additional 375 shares during the period. Commonwealth Equity Services LLC grew its stake in Crispr Therapeutics by 2.2% in the third quarter. Commonwealth Equity Services LLC now owns 18,201 shares of the company’s stock valued at $746,000 after acquiring an additional 386 shares during the period. Farmers & Merchants Trust Co of Chambersburg PA acquired a new position in Crispr Therapeutics in the fourth quarter valued at about $26,000. Finally, Webster Bank N. A. acquired a new position in Crispr Therapeutics in the fourth quarter valued at about $26,000. Institutional investors own 49.83% of the company’s stock.

Crispr Therapeutics Company Profile

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.

Read More: Correction

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Crispr Therapeutics (NASDAQ:CRSP)



Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Source link